Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

LIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

REVENUES:

Sales $489,664 $428,729 $1,408,603 $1,287,802

Other revenues 8,818 9,692 25,813 34,865

498,482 438,421 1,434,416 1,322,667

COSTS AND EXPENSES:

Cost of sales 121,477 82,258 312,711 251,970

Research and development 88,325 93,527 250,169 274,078

Selling, general and

administrative 222,948 186,456 631,832 527,962

Settlement reserve 7,450 369,000 7,450 425,000

Restructuring charges 1,497 - 6,973 -

In-process research and

development - - 10,000 -

441,697 731,241 1,219,135 1,479,010

INCOME (LOSS) FROM

OPERATIONS 56,785 (292,820) 215,281 (156,343)

OTHER INCOME (EXPENSE):

Interest income 4,002 8,868 15,515 23,485

Interest expense (8,831) (5,660) (25,697) (15,272)

Gain on extinguishment of

debt - 5,319 - 5,319

Gain on sale of investment - - - 5,791

Other income (expense), net (2,284) 2,493 1,488 3,747

(7,113) 11,020 (8,694) 23,070

INCOME (LOSS) BEFORE INCOME

TAXES
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the global ... nearly $140 billion in 2013. This is estimated to ... compound annual growth rate (CAGR) of 28.6%. , New ... and exciting possibilities within the broader PCR field. The ...
(Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... 2014 OMICS Group’s 5th International conference ... August, 2014 at Double Tree by Hilton Beijing, China ... in Analytical & Bioanalytical research methods only to facilitate ... this occasion, Dr. Srinubabu Gedela, MD of OMICS Group ... a remarkable one in bringing a unique and international ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... New Mexico, October 29, 2009 Very tiny wires, called ... may play a crucial role as electrical or mechanical ... Making nanodevices work will require a deep understanding of ... fabricated as well as their resultant strengths and weaknesses. ...
... Oct. 29 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ... development of drugs for the treatment of human viral ... not to exercise its option to license IDX184, a ... treatment of HCV. As a result, Idenix retains ...
... Oct. 29 Nektar Therapeutics (Nasdaq: NKTR ) will ... 30, 2009 on Wednesday, November 4, 2009, after the close ... officer, will host a conference call to review the results ... (PT). , The press release and a live audio-only ...
Cached Biology Technology:LANL Roadrunner simulates nanoscale material failure 2Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 2Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 3Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets 2
(Date:7/11/2014)... Canyon fire started near the City of Entiat on ... resources, the fire quickly grew to over 1,000 acres ... the fire is under investigation by the Washington Department ... with existing local resources in developing fire control strategies ... (USFS), Washington State Department of Natural Resources, (WA DNR), ...
(Date:7/11/2014)... National Institute of Standards and Technology (NIST) need ... effectively, they often prove that necessity is truly ... recently for M. Lorna De Leoz and Stephen ... of glycomics. Glycomics is the study of the ... attached to proteins and lipids and influence cellular ...
(Date:7/11/2014)... Sweden, have explored two different ways that allow ... to the formation of oxygen molecules in photosynthesis. ... scientific journal Nature Communications . , "The ... catalysts for water oxidation, which are key components ... storage of solar energy in fuels like hydrogen, ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... forest cover in the eastern United States in recent decades ... analysis published in the April 2010 issue of BioScience ... A. Drummond and Thomas R. Loveland of the US Geological ... were cleared for agriculture on a large scale, but from ...
... Four billion years ago, our then stripling sun radiated only 70 ... things on Earth being equal, with so little energy reaching the ... But ancient rocks hold ample evidence that the early Earth was ... something must have compensated for the reduced solar output and kept ...
... DURHAM, N.C. The number of sea turtles inadvertently ... years may reach into the millions, according to the ... from gillnet, trawl and longline fisheries worldwide. The ... journal Conservation Letters , analyzed data compiled ...
Cached Biology News:Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet 2Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet 3Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet 4Commercial fishing estimated to kill millions of sea turtles 2Commercial fishing estimated to kill millions of sea turtles 3
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
Plasmid expressing PLAP reporter gene....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
...
Biology Products: